Mixed Chimerism after Allogeneic Stem Cell Transplantation – Focus on Double Cord Blood Transplantation

Gertow Jens1,2, Stikvoort Arwen1, Watz Emma1,2, Mattsson Jonas1,2 and Uhlin Michael1,2*

1Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Sweden
2Department of Laboratory Medicine, Division of Theurapeutical Immunology, Karolinska Institute, Sweden
3Department of Clinical Immunology and Transfusion Science, Karolinska University Hospital, Sweden

Abstract

Allogeneic hematopoietic Stem Cell Transplantation (ASCT) is well established as a curative treatment for many hematological malignancies and non-malignant disorders. The aim of ASCT in these diseases is to achieve sustained donor engraftment to fight leukemic cells in malignant disease, improve hematopoietic function, provide immune competence or normalize enzyme deficiency. Peripheral blood or bone marrow is commonly used to monitor engraftment after ASCT. The presence of mixed donor/recipient chimerism after transplantation, donor/donor chimerism after double cord blood transplantation can be used and interpreted differently based on the initial disease status. In patients with malignant diseases, chimerism is primarily used to detect early relapse but can also indicate threatening rejection. In individuals with non malignant disease, chimerism is merely used to monitor successful engraftment. After double cord blood transplantation, the unique situation with two existing donor immune systems can occur. Most often one of the immune systems rapidly succumbs with one immune system prevailing, but in certain situations mixed donor/donor chimerism can exist for prolonged periods. This review describes the importance of mixed chimerism and the possible interpretation after ASCT in patients with both malignant and non-malignant diseases. It also focuses specifically on the situation and mechanisms donor/donor chimerism after double cord blood transplantation.

Keywords: Mixed chimerism; Allogeneic; Stem cell transplantation

Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation (SCT) is used as a curative treatment for leukemic malignancies, genetic defects in metabolism or immune function and certain solid tumors [1-3]. Historically SCT was performed with bone marrow and subsequently peripheral blood as stem cell source [4]. Two decades ago cord blood was added as a third possible source [5].

The post-transplant management of allogeneic SCT is associated with several lethal complications. Most complications are associated with compromised immune function during the neutropenic and later leukopenic phase, or are due to the action of, or interactions between, the host and the donor immune systems [6-9]. Additionally, the decrease in immune function post transplant often results in opportunistic viral, bacterial and/or fungal infections [7,10,11]. Due to these complications the immunosuppressive management must be closely monitored in order not to unnecessarily extend or worsen this crucial period [12,13]. However, if the level of immunosuppression is too low, rejection and increased Graft Versus Host Disease (GVHD) frequencies might be unwanted consequences [14].

Infections can be monitored and fought with standard antimicrobial regimens, common in many hospital routines, while rejection and GVHD demand more specialized immunological methods and therapies [15-17].

Graft Versus Leukaemia as an Immunological Tool after SCT

Already two decades ago, the use of Donor Lymphocyte Infusions (DLI) was initiated to treat threatening relapse of the underlying malignant disease after SCT by increasing the Graft Versus Leukaemia effect (GVL) [18-20]. The GVL effect is mediated by donor-derived allogeneic T cells directly attacking the leukemic cells [2]. This advantageous effect was elegantly described by Horowitz et al. [21] who observed that patients who received identical twin transplants had an increased probability of relapse compared with allograft recipients. It was further shown that if T cells were depleted this risk was once again increased. Unfortunately this beneficial GVL effect is most often associated with an elevated risk for Graft Versus Host Disease (GVHD), where allogeneic T cells attack cells of non-malignant origin in the recipient [16,21].

Initially all SCT patients received a Myeloablative pre-Conditioning (MAC). The conditioning treatment has two major aims: reduce the tumour burden (when the disease is neoplastic) and eliminate the recipient’s immune system, in order to allow engraftment of new stem cells. MAC involves heavy chemotherapy and irradiation leaving the patient fully dependent on the new, engrafted hematopoietic stem cells. The severe toxic effects associated with this treatment have limited the use of SCT on elderly and seriously ill patients [22,23].

In the past two decades two changes have occurred in conditioning regimens in order to remedy this: the introduction of Fludarabine and dose reductions of the alkylating agents or Total Body Irradiation (TBI) [24,25]. These regimens were specifically designed for patients ineligible for MAC, either because of age or due to the presence of co-morbidities [26,27]. By reducing the conditioning intensity, the benefit of allogeneic SCT would generally come from a graft-versus-malignancy effect, who observed that patients who received identical twin transplants had an increased probability of relapse compared with allograft recipients. It was further shown that if T cells were depleted this risk was once again increased. Unfortunately this beneficial GVL effect is most often associated with an elevated risk for Graft Versus Host Disease (GVHD), where allogeneic T cells attack cells of non-malignant origin in the recipient [16,21].

Initially all SCT patients received a Myeloablative pre-Conditioning (MAC). The conditioning treatment has two major aims: reduce the tumour burden (when the disease is neoplastic) and eliminate the recipient’s immune system, in order to allow engraftment of new stem cells. MAC involves heavy chemotherapy and irradiation leaving the patient fully dependent on the new, engrafted hematopoietic stem cells. The severe toxic effects associated with this treatment have limited the use of SCT on elderly and seriously ill patients [22,23].

In the past two decades two changes have occurred in conditioning regimens in order to remedy this: the introduction of Fludarabine and dose reductions of the alkylating agents or Total Body Irradiation (TBI) [24,25]. These regimens were specifically designed for patients ineligible for MAC, either because of age or due to the presence of co-morbidities [26,27]. By reducing the conditioning intensity, the benefit of allogeneic SCT would generally come from a graft-versus-malignancy effect,
rather than from the cyto-reductive effect of the conditioning regimen [28,29]. These modified regimens have been referred to as Reduced Intensity Conditioning (RIC) [30,31]. Today approximately 80% of all transplants are performed with reduced intensity regimens [32,33].

After a successful ASCT, the patient/recipient usually adopts the donor hematopoietic system and becomes a full donor chimera. However, in some cases after ASCT, recipient hematopoietic cells remain and the patient instead becomes a mixed chimera. A patient is considered to be a mixed chimera if 5-95% of its hematopoietic cells are of donor origin [34]. Some patients are only mixed chimeras for certain subsets, e.g. NK cells or erythrocytes [17,35,36]. Depending on treatment prior to ASCT, patients are more inclined to become either mixed chimeras or donor chimeras. In many situations it may be informative and even crucial to evaluate the development of donor chimerism after SCT. For example, it could allow early detection of rejection of the new hematopoietic system, where the chimerism analysis would indicate a rising percentage of recipient cells in bone marrow or peripheral blood [15,37]. This is also true for detection of early relapse where an increasing amount of recipient cells in the cell lineage with the same origin as the leukemia is observed [38-40].

**Chimerism Analysis after Stem Cell Transplantation**

Since chimerism analyses were first performed, many different methods have been developed and implemented all following the same basic principle of analyzing differences in polymorphic markers in the genome and their products between the recipient and the donor. The wide clinical use for these analyses came when PCR methods were developed in the 1990s. Different methods have been used during the last 20 years (reviewed in [17]) but today most modern clinical immunology laboratories use either characterization of Short Tandem Repeat (STR) markers by fluorescent labelling of the PCR primers and resolution of products with capillary electrophoresis or real-time PCR techniques aimed at the amplification of Single-Nucleotide Polymorphisms (SNPs) [41,42]. SNPs are bi-allelic variants that differ from each other at a single nucleotide and occur on average very frequently in the human genome. In contrast to earlier methods having only 8-10 markers, with the real time based method PCR based methods, where virtually all donor/recipients pairs could be characterized, with 8-10 markers, with the real time based method much more markers (>15) are needed in order to reach the same level of information. Real-time PCR also suffers from less quantitative accuracy compared to the STR systems when high levels of recipient product are detected. However, the real-time PCR method is at least one log of magnitude more sensitive than the STR-based method and therefore more suited to detect low levels of leukemia cells.

**The Different Roles of Mixed Chimerism after Allogeneic Stem Cell Transplantation – The Importance of Circumstances**

Historically, mixed chimerism post-SCT was considered to be detrimental for the recipient and always a warning sign for either rejection or malignant relapse [17]. However, this view is today more nuanced and it has become clear that donor and recipient hematopoietic cells can, in certain situations, coexist for prolonged periods [43-45].

**Mixed Donor Recipient Chimerism after Allogeneic Stem Cell Transplantation – Malignant Diseases**

Using current chimerism detection methods, it is impossible to determine whether the emergence of reappearing or persisting recipient cells post-SCT is a mere manifestation for survival of normal healthy hematopoietic cells, leukemic cells or both. In patients with e.g. Chronic Myeloid Leukemia (CML) several studies have demonstrated that the occurrence of recipient cells precedes a relapse [46-48]. Hence, mixed chimerism is considered to be associated with a reduced existing GVL effect in this patient category.

In patients with acute leukemia the situation is not as clear-cut. Some studies could show that mixed chimerism after SCT had no correlation with malignant relapse [49,50] while others found the opposite [51,52]. These differences conflicting results can most likely be attributed to differences in study populations. In a recent study in children with AML, patients with mixed chimerism were offered immunotherapeutic treatment solely based on chimerism data. Half of these patients could be turned into full Donor Chimerism (DC) without relapse. Of non-treated patients with Mixed Chimerism (MC) all relapsed [53]. These results are also supported by a larger study where patients with acute leukemia and myelodysplastic syndrome showed a 3-year survival of 42% if DLI treatment was given because of molecular evidence of mixed chimerism, compared to 16% in hematologic relapse [20].

In another study focused on children with Acute Lymphoblastic Leukemia (ALL), it was shown that treatment of threatening relapse, as defined by an emerging MC pattern could be treated by immunotherapeutic measurements [54]. It is important to mention that due to the low sensitivity of the chimerism assays (>1-5%) in many cases immune therapeutical intermission may be too late [55].

What is universal for many of these studies is the importance of serial chimerism measurements [39,40,45]. Several consecutive measurements are required to disregard natural fluctuations, especially when evaluating the possibility to prevent relapse by pre-emptive immunotherapy on the basis of chimerism analysis in patients with acute leukemia. Proposed guidelines from different centers are weekly or bi weekly until 200 days post transplantation [17,38].

**Mixed Donor Recipient Chimerism after Allogeneic Stem Cell Transplantation – Non-Malignant Diseases**

As stated before, SCT is the cure to a variety of non-malignant diseases, varying from hemoglobinopathies, e.g. thalassemia and sickle cell diseases, to diseases such as Severe Aplastic Anemia (SAA), leukodystrophies and Wiskott-Aldrich Syndrome (WAS) [56]. For all of these diseases, incidences of mixed chimerism after SCT have been reported.

While the occurrence of MC might be associated with relapse in patients with malignant diseases, there is no fear of this happening in patients with non-malignant diseases. In many cases the implementation of a state of mixed chimerism is mostly sufficient to improve the patient’s disease status and well-being and due to this physicians tend to have a greater tolerance for MC. As a result, more literature exists on the phenomenon of mixed chimerism in non-malignant patients than in malignant patients after SCT.

For non-malignant patients, the first two years post-SCT are considered the most critical regarding chimerism status with most individuals either rejecting the graft or becoming full donor chimeras during that time [57]. Due to this, most patients with mixed chimerism are not followed up for longer than 1 to 2 years post-SCT [17,58-60].

During this initial period (< 2 years) some studies have shown that a high mixed chimerism of over 30% recipient leads to increased risk of graft rejection [61-63] while others have failed to confirm this [60,64]. Only a very small portion of patients have been reported to still
be mixed chimeras after this period [43,58]. Historically, patients with stable mixed chimerism have been pushed into full donor chimerism via the administration of DLI. However, more current studies, indicate that this may not be necessary for all mixed chimerism in non-malignant patients post-SCT [62,65]. If these observations hold true, the need for DLI would decrease in this patient category and hence the risk of GVHD would putatively be lowered. One case study on a patient with stable mixed chimerism several years post SCT has shown no obvious negative side effects. This patient still remains disease free and has not rejected, even after a prolonged period of time [43].

What happens in patient with stable mixed chimerism is unknown. It is plausible that either the immune system of the recipient or donor is pre-dominant, but this has of yet not been confirmed in studies [62,65].

**Mixed Donor/Donor Chimerism after Double Cord Blood Transplantation**

During the early nineties, transplantation centers began utilizing unrelated umbilical cord blood as an alternative stem cell source for patients lacking an HLA-matched adult donor [66-68]. As the cell dose of an umbilical cord is limited and often relatively low historically the majority of patients enrolled were children [69,70]. To make cord blood an option also for adult patients Double Cord Blood Transplantation (DCBT) was introduced [71]. In this treatment modality, used for patients with both malignant and non-malignant underlying diseases [72], two matched or par-tially matched cord blood units are co-transplanted.

Even though a mixed donor/donor chimerism is commonly seen during the first few weeks after transplantation [71,73,74], one of the CB units generally prevails and the sustained hematopoiesis is derived from a single CB unit [75-77]. However, in rare instances a long-term, stable donor/donor chimerism develops after double cord blood transplantation. To our knowledge, eight published studies have described this phenomenon at day 60 or more after transplantation [45,75,78-83] and for five of the described patients in these studies the double chimerism was apparent for over one year post-transplantation [45,81-83]. Thus, out of at least a thousand DCBTs performed to date [72], only a handful of stable donor/donor chimeras have been described.

Understanding the factors determining engraftment of cord blood units after DCBT may have implications for graft-selection, where, for example, two units with high probability of long-term engraftment could be chosen. Several studies have therefore tried to elucidate predictive factors for unit predominance [71,75,77,84-88], which rationally are the same as knowing the factors generating mixed donor/ donor chimerism.

Since stem cell dose is determinative in choosing DCBT over single unit cord blood transplantation, one would think that the CD34+ cell dose of a cord blood unit is a predictive factor for unit predominance. Studies of this notion have had conflicting results. Whereas both Verneris et al. [89] in a study of 93 patients as well as Ramirez et al. [84] in a study of 262 patients with hematologic malignancies found no correlation between CD34+ dose and unit predominance, Avery et al. [77] did indeed find such a correlation in a study of 84 patients [75,77,84]. Of course, high CD34+ cell content is of no use if the progenitor cells are not viable. In the same study, Avery et al. [77] showed that the percentage of viable CD34+ was associated with engraftment and unit dominance. This finding has been endorsed by a prospective study where cord blood units with high fraction of viable cells were co-transplanted with a unit of low viability. In 15 out of 16 cases, the high CD34+ viability unit engrafted [85].

Importantly, the cord blood graft does not only contain progenitor cells. Verneris et al. [89] suggested in 2005 that a higher CD3+ cell dose in a cord blood unit was associated with becoming predominant [71]. Although refuted by the same group in a larger study [75], this suggestion has now been supported in both a myeloablative and RIC setting [77,84].

The observations that CD3+ cell dose is a predicting factor for predominance has spurred the hypothesis that the “winning” unit develops an immune reaction towards the other unit and rejects it. Corroborating this hypothesis are discoveries that DCBTs have increased GVHD and lower relapse rates compared to single CBTs [75,89] and that patients with mixed donor/donor chimerism after RIC still can develop chronic GVHD [88]. Furthermore, a human/ murine xenotransplantation model showed that after positive selection of CD34+ cells and subsequent DCBT, mixed donor/donor chimerism was very frequent. When, however, CD34- cells from one CB unit were infused to the transplanted animal, single-unit dominance of that same CB unit was induced [86].

In a DCBT setting, immune interactions could develop between the two cord blood units as well as between the units and the recipient. The degree of HLA match between the two units and between units and recipient may therefore play a role in the engraftment process. Conflicting results have been reported here. In the RIC setting, Brunstein et al. [75] found no correlation between HLA match and unit predominance, whereas a more recent study indeed did show a correlation between these parameters [75,84].

In the myeloablative setting, donor-recipient HLA disparity had no influence on engraftment, but although unit-unit HLA match also did not affect engraftment, closely matched units were more likely to co-engraft initially [77]. This finding is in line with the hypothesis of immune interactions between the two cord blood units, since a close HLA-match could indicate a tolerance for one another.

Compelling evidence for a graft-versus-graft interaction came when Gutman et al. [87] showed that in 9 out of 10 patients with single unit dominance, a significant subset of CD8+ T cells derived from the engrafting unit produced interferon (IFN-γ) in response to the non-engrafting unit [87]. Moreover, in three patients with persistent mixed donor/donor chimerism no significant IFN-γ producing cells were detected after similar stimulations. These cells were however detected only transiently after transplantation and the antigens to which the CD8+ T cells respond remain unknown. An interesting in vitro model system based on a two-way Mixed Lymphocyte Culture (MLC) was recently presented by Moretta et al. [90] as a tool to identify the potentially predominant CB unit even before DCBT. As in the study by Gutman, it was proposed that the dominant CB unit to a higher degree developed allo-antigen induced cytotoxicity against the other graft.

The described CD8+ T cells should probably not be held accountable as the only cause of rejection, partly because T cells are not the only cells responding to HLA molecules. Natural Killer (NK) cell function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules. The majority of KIRs respond to just two known epitope molecules. The function is to a high extent regulated by inhibitory and activating Killer Cell Immunoglobulin-like Receptors (KIRs) that recognize certain HLA molecules.
in the DCBT setting has not yet been investigated. However, our group observed a complete HLA-C match between units in a study of the phenotypes and functionality of the two immune systems in two patients with long-term stable donor/donor chimerism [44]. Patients in this study were conditioned with high-dose Anti-Thymocyte Globulin (ATG) depleting the grafts of T cells in vivo [93] and putatively reducing the potential for T cell mediated rejection in any direction for a prolonged time. The absence of T cells could allow NK cells to expand more freely and in a KIR/HLA-C mismatched situation lead to unit rejection, or, as in the described situation of HLA-C match lead to tolerance.

However, since the use of ATG or other forms of T cell depletion method was not mentioned in but a few of the eight referred publications of mixed donor/donor chimerism [45,75,78], T cell depletion does not seem to be required for the development of a double chimera.

Our group has also demonstrated that, the two cord blood units had in a mixed donor chimera had comparable T cell receptor repertoires but were phenotypically and functionally different [44]. In both patients one unit occupied a larger part of the immune system with T and NK cells responding to stimuli by producing cytokines in a manner similar to an immune system developed after single unit dominance. In contrast, the other unit occupied a minor part of the total immune system and was more non-responsive and accordingly had a more naive T cell phenotype. Consequently, in comparison to patients with single unit dominance, the two systems together in the patients with mixed donor/donor chimerism had a more naive phenotype and a decreased functionality. Thus, while this study contains only two patients, having a double chimerism is probably not an advantage compared to having single unit dominance. On the other hand, some double chimeras described have been without complications still up to 66 months after transplantation [45,83].

Even in a long-term mixed chimerism situation the immune systems are successful to varying degrees in repopulating their host [44] and in one case dominance reversion has been observed as late as 133 days post-transplantation [81]. These findings could be a reflection of immune reactions between the two cord blood grafts as well as with the recipient in these patients. Although contested by the findings that grafts of mixed chimeras have no significant IFN-γ production in response to one another [87], the intensity of the immune reactions could putatively be there but not strong enough for either graft rejection or detection by flow cytometry.

Another plausible explanation for unit predominance is yet unresolved intrinsic properties of the CD34+ progenitor cells leading to e.g. diverse bone marrow homing potential. Support for this comes from ex vivo expansion studies showing extremely variable proliferative potential of progenitor cells between cord blood units [87]. Likewise, our group has studied ex vivo proliferation potential of cord blood CD34+ T cells and observed huge differences ranging from 0 to over thousand fold expansion in a matter of days [94].

As seen, several possible and probable factors lead to the development of a mixed donor/donor chimerism. Future studies will reveal if graft selection can be improved and will shed light on whether mixed donor/donor chimerism should be strived for, eliminated or be left unaddressed.

References


